U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C9H10N4O4.C8H19NO
Molecular Weight 383.4433
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACEFYLLINE HEPTAMINOL

SMILES

Cn1c2c(c(=O)n(C)c1=O)n(CC(=O)O)cn2.CC(CCCC(C)(C)O)N

InChI

InChIKey=DWOMKMOQZYKZKX-UHFFFAOYSA-N
InChI=1S/C9H10N4O4.C8H19NO/c1-11-7-6(8(16)12(2)9(11)17)13(4-10-7)3-5(14)15;1-7(9)5-4-6-8(2,3)10/h4H,3H2,1-2H3,(H,14,15);7,10H,4-6,9H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C9H10N4O4
Molecular Weight 238.2005
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C8H19NO
Molecular Weight 145.2429
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Acefylline is a stimulant drug of the xanthine chemical class. It acts as an adenosine receptor antagonist. Acephylline piperazine is a theophylline derivative with a direct bronchodilator action. It has the advantages over theophylline in being far less toxic and producing minimal gastric irritation. It is indicated for the treatment of asthma, emphysema, acute and chronic bronchitis associated with bronchospasm.Acefylline relaxes smooth muscles, relieves bronchospasm & has a stimulant effect on respiration. It stimulates the myocardium & central nervous system, decreases peripheral resistance & venous pressure & causes diuresis. The mechanism of action is still not clear, inhibition of phosphodiesterase with a resulting increase in intracellular cyclic AMP does occur, but not apparently at concentrations normally used for clinical effect. Other proposed mechanisms of action include adenosine receptor antagonism, prostaglandin antagonism & effects on intracellular calcium. Sodium phenobarbital is a non-selective central nervous system depressant that is primarily used as sedative-hypnotic.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
27.6 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Etaphylline

Approved Use

Etaphylline is primarily indicated in conditions like Bronchitis, Bronchospasm, Emphysema, and can also be given in adjunctive therapy as an alternative drug of choice in Asthma, Biliary colic, Cardiac insufficiency.
Primary
Etaphylline

Approved Use

Etaphylline is primarily indicated in conditions like Bronchitis, Bronchospasm, Emphysema, and can also be given in adjunctive therapy as an alternative drug of choice in Asthma, Biliary colic, Cardiac insufficiency.
Primary
Etaphylline

Approved Use

Etaphylline is primarily indicated in conditions like Bronchitis, Bronchospasm, Emphysema, and can also be given in adjunctive therapy as an alternative drug of choice in Asthma, Biliary colic, Cardiac insufficiency.
Primary
Etaphylline

Approved Use

Etaphylline is primarily indicated in conditions like Bronchitis, Bronchospasm, Emphysema, and can also be given in adjunctive therapy as an alternative drug of choice in Asthma, Biliary colic, Cardiac insufficiency.
PubMed

PubMed

TitleDatePubMed
Esterification of 7-theophyllineacetic acid with diethylene glycol monomethyl ether.
2006 Jun
Development and validation of chemometrics-assisted spectrophotometric and liquid chromatographic methods for the simultaneous determination of two multicomponent mixtures containing bronchodilator drugs.
2007 Feb 19
Acebrophylline: an airway mucoregulator and anti-inflammatory agent.
2007 Jun
Solid-state chemistry of ambroxol theophylline-7-acetate.
2007 May
Molecularly imprinted polymers for ochratoxin a extraction and analysis.
2010 Jun
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Can be used orally: Dosage: 2 to 6 tablets daily, in several doses at regular intervals during the day. Composition: Each coated tablet contains: - Acefylline piperazine 0.250 g http://www.unipharma-sy.com/en/MedicineView/48/142/ETAPHYLLINE_.aspx
Dosage & route of administration & duration: The optimum therapeutic serum concentration is considered to range from 10 to 20 mcg/ml To avoid adverse effects the rate of infusion administration should not exceed 20 mg / min For I.M & slow I.V injection of 200 mg over at least 15 min. For IV infusion a loading dose of 4 mg/kg may be given over 20 to 30 min followed by a suggested maintenance dose of 0.5 mg /kg / hour reduced after 12 hours to 0.4 mg/kg/hour. Suggested Doses for children: 4mg/Kg by slow IV injection over at least 15 min or by infusion with a loading dose of 4 mg/kg followed by maintenance doses of: Children from 6 months to 6 years...................0.8 to 1 mg/kg/hour, reduced after the first 12 hours to 0.6 mg/kg/hour. Children over 6 years.....................................0.75 mg/kg/hour, reduced after the first 12 hours to 0.5 mg/kg/hour.
Route of Administration: Parenteral
After topical application of a gel formulation containing 3% acefylline at the surface of reconstructed human epidermis, immunoblotting analysis showed an increase in the total amount of deiminated proteins, and confocal microscopy showed an enhanced deimination in the stratum corneum. This demonstrated the activation of PADs in living cells.
Substance Class Chemical
Created
by admin
on Sat Jun 26 13:52:42 UTC 2021
Edited
by admin
on Sat Jun 26 13:52:42 UTC 2021
Record UNII
WL6JNI78OE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACEFYLLINE HEPTAMINOL
Common Name English
7H-PURINE-7-ACETIC ACID, 1,2,3,6-TETRAHYDRO-1,3-DIMETHYL-2,6-DIOXO-, COMPD. WITH 6-AMINO-2-METHYL-2-HEPTANOL (1:1)
Common Name English
HEPTAMINOL ACEFYLLINATE [MART.]
Common Name English
HEPTAMINOL ACEFYLLINE
WHO-DD  
Common Name English
HEPTAMINOL ACEFYLLINE [WHO-DD]
Common Name English
HEPTAMINOL ACEFYLLINATE
MART.  
Common Name English
COROPHYLLINE
Common Name English
TETRAHYDRO-1,3-DIMETHYL-2,6-DIOXO-7H-PURINE-7-ACETIC ACID COMPD. WITH 6-AMINO-2-METHYLHEPTAN-2-OL (1:1)
Systematic Name English
CARIAMYL
Brand Name English
Code System Code Type Description
RXCUI
236292
Created by admin on Sat Jun 26 13:52:43 UTC 2021 , Edited by admin on Sat Jun 26 13:52:43 UTC 2021
PRIMARY RxNorm
ECHA (EC/EINECS)
233-205-0
Created by admin on Sat Jun 26 13:52:43 UTC 2021 , Edited by admin on Sat Jun 26 13:52:43 UTC 2021
PRIMARY
EVMPD
SUB02487MIG
Created by admin on Sat Jun 26 13:52:43 UTC 2021 , Edited by admin on Sat Jun 26 13:52:43 UTC 2021
PRIMARY
CAS
10075-18-0
Created by admin on Sat Jun 26 13:52:43 UTC 2021 , Edited by admin on Sat Jun 26 13:52:43 UTC 2021
PRIMARY
FDA UNII
WL6JNI78OE
Created by admin on Sat Jun 26 13:52:43 UTC 2021 , Edited by admin on Sat Jun 26 13:52:43 UTC 2021
PRIMARY
PUBCHEM
3084058
Created by admin on Sat Jun 26 13:52:43 UTC 2021 , Edited by admin on Sat Jun 26 13:52:43 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY